Comparison of Actual Hospital Costs versus DRG Revenues for In-Patient Treatment of Febrile Neutropenia during Adjuvant Anthracycline plus/minus Taxane-Based Chemotherapy for Primary Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|34|11|614-618

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.11, 2011-10, pp. : 614-618

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

By  

THE BREAST JOURNAL, Vol. 21, Iss. 6, 2015-11 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 274-282

Karger

Access to resources Recommend Favorite

Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-04 ,pp. : 213-219

Karger

Access to resources Recommend Favorite

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 3, 2018-03 ,pp. : 490-500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 476-478

Karger

Access to resources Recommend Favorite